SeaX Ventures, a venture capital firm headquartered in San Francisco with office in Bangkok, has helped US medical technology company Skribe Medical run clinical research in Southeast Asia, connecting the startup with hospital partners and recruiting more than 100 patients for its studies.

In a statement on Wednesday, Skribe said it is developing a wearable patch and AI software that estimate left ventricular ejection fraction, the share of blood pushed out by the heart’s main pumping chamber with each beat. Oncologists use that measure to watch for heart damage caused by some cancer treatments.

Skribe device, called Aurora, can fit into oncology visits, with a longer-term goal of home monitoring. More than 800 patients have enrolled in its NOECHO study across 10 US sites and one site in Southeast Asia.

SeaX led Skribe’s pre-seed round of $1.65 million, featured GoAhead Ventures and Marin Sonoma Impact Ventures as participants. The round has funded technology development and clinical research.

Kid Parchariyanon, managing partner of SeaX Ventures, said the firm’s work with Skribe puts its investment thesis into practice. “For deep-tech founders, access to capital is only part of the challenge. They also need the right clinical partners to build evidence and a credible path to market,” he said. SeaX aims to connect US innovation with Southeast Asia’s clinical expertise and hospital networks, to help founders move from development toward commercialization.

SeaX has worked with more than 500 listed companies, multinationals, and major family businesses in Southeast Asia. The firm invests at pre-seed through growth-equity stages.

Melazyme raises $2M seed round from Thailand-based SeaX to scale precision fermentation platform